Biotechnology News and Research

RSS

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers.

3 Mar 2015

Experts review diagnostic approaches to treat obstructive coronary artery disease in women

Obstructive coronary artery disease (CAD) in women often presents with different types of symptoms than in men and can be challenging to diagnose due to a variety of factors. A national panel of experts convened to review the latest evidence regarding CAD in women, diagnostic approaches, and new types of tests and technologies.

3 Mar 2015

BioMed Realty recaptures valuable properties in Cambridge innovation district

BioMed Realty Trust, Inc. (NYSE: BMR) today announced it has recaptured approximately 313,000 square feet of space in the most dynamic and valuable life science real estate market in the world through the termination of Vertex Pharmaceuticals' leases on three properties in Cambridge, Massachusetts effective February 28, 2015.

2 Mar 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

2 Mar 2015

Modified measles vaccine effective against Chikungunya virus, study finds

A modified, conventional measles vaccine has the potential to act against the Chikungunya virus. This is the result of a study at the University Clinic for Clinical Pharmacology of the MedUni Wien (Medical University of Vienna), which has now been published in the top journal "The Lancet Infectious Diseases".

2 Mar 2015

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355).

28 Feb 2015

New strategy may ensure safety of adult epidermal stem cells before performing treatments

A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria.

28 Feb 2015

Intrexon signs agreement to acquire Okanagan Specialty Fruits

Intrexon Corporation, a leader in synthetic biology, today announced it has entered into an agreement to acquire Okanagan Specialty Fruits, the pioneering agricultural company behind the Arctic apple, the world's first non-browning apple.

27 Feb 2015

TxCell invited to speak at largest US meeting for investors in emerging growth companies

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference.

27 Feb 2015

Single-step fermentative method may facilitate industrial-scale statin drug production

University of Manchester researchers, together with industrial partner DSM, have developed a single-step fermentative method for the production of leading cholesterol-lowering drug, pravastatin, which will facilitate industrial-scale statin drug production.

27 Feb 2015

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

Study: Plant compounds can help prevent liver damage during menopause

Women going through menopause often struggle with weight gain that results when their estrogen levels drop, and many turn to weight-loss supplements to help them shed those extra pounds. But those supplements may cause an accumulation of fat in the liver and a potentially life-threatening condition called non-alcoholic fatty liver disease.

26 Feb 2015

Researchers develop revolutionary approach to treat drug-resistant tumors

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy.

25 Feb 2015

Garlic compound can help fight lung infections in people with cystic fibrosis

A chemical found in garlic can kill bacteria that cause life-threatening lung infections in people with cystic fibrosis, research suggests.

25 Feb 2015

Kuros Biosurgery granted U.S. patent for synthetic hydrogel technology

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced today that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947.

24 Feb 2015

Roche, BioMed X partner to develop novel nanomaterial-based biosensors

Roche and BioMed X announced today that they have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene.

From Roche Sequencing and Life Science 24 Feb 2015

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.

24 Feb 2015

New study could lead to better remedies for insomnia, more effective anaesthetic drugs

Scientists have discovered that switching on one area of the brain chemically can trigger a deep sleep.

24 Feb 2015

Mayo Clinic researchers identify molecule that lays groundwork for development of pancreatic cancer

A research team led by investigators from Mayo Clinic's campus in Jacksonville, Florida, and the University of Oslo, Norway, have identified a molecule that pushes normal pancreatic cells to transform their shape, laying the groundwork for development of pancreatic cancer -- one of the most difficult tumors to treat.

21 Feb 2015

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).

20 Feb 2015

Biotechnology News and Research

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Experts review diagnostic approaches to treat obstructive coronary artery disease in women

BioMed Realty recaptures valuable properties in Cambridge innovation district

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Modified measles vaccine effective against Chikungunya virus, study finds

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

New strategy may ensure safety of adult epidermal stem cells before performing treatments

Intrexon signs agreement to acquire Okanagan Specialty Fruits

TxCell invited to speak at largest US meeting for investors in emerging growth companies

Single-step fermentative method may facilitate industrial-scale statin drug production

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

Study: Plant compounds can help prevent liver damage during menopause

Researchers develop revolutionary approach to treat drug-resistant tumors

Garlic compound can help fight lung infections in people with cystic fibrosis

Kuros Biosurgery granted U.S. patent for synthetic hydrogel technology

Roche, BioMed X partner to develop novel nanomaterial-based biosensors

Shire announces acquisition of Meritage Pharma

New study could lead to better remedies for insomnia, more effective anaesthetic drugs

Mayo Clinic researchers identify molecule that lays groundwork for development of pancreatic cancer

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News